Review





Similar Products

rt-cgm dexcom g4  (Dexcom Inc)
90
Dexcom Inc rt-cgm dexcom g4
Main findings and highlights resulted by the systematic review
Rt Cgm Dexcom G4, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rt-cgm+dexcom+g4/dexcom+g4/pmc11470883-7-31-33
Average 90 stars, based on 1 article reviews
rt-cgm dexcom g4 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
rt-cgm dexcom g4 platinum system  (Dexcom Inc)
90
Dexcom Inc rt-cgm dexcom g4 platinum system
Summary Results of Base Case Analysis
Rt Cgm Dexcom G4 Platinum System, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rt-cgm+dexcom+g4/dexcom+g4+platinum/pmc08366033-81-50-53
Average 90 stars, based on 1 article reviews
rt-cgm dexcom g4 platinum system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier
rt-cgm dexcom g4 platinum  (Dexcom Inc)
90
Dexcom Inc rt-cgm dexcom g4 platinum
Study characteristics and significant results, ordered by intervention and control devices.
Rt Cgm Dexcom G4 Platinum, supplied by Dexcom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rt-cgm+dexcom+g4/dexcom+g4+platinum/pmc06719474-9-12-13
Average 90 stars, based on 1 article reviews
rt-cgm dexcom g4 platinum - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Main findings and highlights resulted by the systematic review

Journal: Reviews in Endocrine & Metabolic Disorders

Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

doi: 10.1007/s11154-024-09903-y

Figure Lengend Snippet: Main findings and highlights resulted by the systematic review

Article Snippet: Peeks et al. 2021 [ ] , 1°subset: n.1 GSDIa; 2° subset: n. 11 GSDs, 3° subset: n.3 GSDIb , 1°subset: 9y; 2°subset:2-22y; 3°subset: 2-11y , Rt-CGM , 1°, 3° subsets: Dexcom G6 (Dexcom), non-blinded; 2° subset Dexcom G4 (Dexcom), blinded , 1°subset: 5 days; 2°subset: 1 day; 3°subset: 30 days , 1° subset: case series (single case report); 2° subset: controlled intervention (prospective, randomized, double blind cross-over); 3° subset: pre-post without control group (retrospective) , 1° subset: fair; 2° subset: poor; 3° subset: poor.

Techniques: Control

Rt-CGM/FGM in GSDs: population features, devices and study design

Journal: Reviews in Endocrine & Metabolic Disorders

Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

doi: 10.1007/s11154-024-09903-y

Figure Lengend Snippet: Rt-CGM/FGM in GSDs: population features, devices and study design

Article Snippet: Peeks et al. 2021 [ ] , 1°subset: n.1 GSDIa; 2° subset: n. 11 GSDs, 3° subset: n.3 GSDIb , 1°subset: 9y; 2°subset:2-22y; 3°subset: 2-11y , Rt-CGM , 1°, 3° subsets: Dexcom G6 (Dexcom), non-blinded; 2° subset Dexcom G4 (Dexcom), blinded , 1°subset: 5 days; 2°subset: 1 day; 3°subset: 30 days , 1° subset: case series (single case report); 2° subset: controlled intervention (prospective, randomized, double blind cross-over); 3° subset: pre-post without control group (retrospective) , 1° subset: fair; 2° subset: poor; 3° subset: poor.

Techniques: Control

Rt-CGM/FGM in CH: population features, devices and study design

Journal: Reviews in Endocrine & Metabolic Disorders

Article Title: Continuous glucose monitoring in patients with inherited metabolic disorders at risk for Hypoglycemia and Nutritional implications

doi: 10.1007/s11154-024-09903-y

Figure Lengend Snippet: Rt-CGM/FGM in CH: population features, devices and study design

Article Snippet: Peeks et al. 2021 [ ] , 1°subset: n.1 GSDIa; 2° subset: n. 11 GSDs, 3° subset: n.3 GSDIb , 1°subset: 9y; 2°subset:2-22y; 3°subset: 2-11y , Rt-CGM , 1°, 3° subsets: Dexcom G6 (Dexcom), non-blinded; 2° subset Dexcom G4 (Dexcom), blinded , 1°subset: 5 days; 2°subset: 1 day; 3°subset: 30 days , 1° subset: case series (single case report); 2° subset: controlled intervention (prospective, randomized, double blind cross-over); 3° subset: pre-post without control group (retrospective) , 1° subset: fair; 2° subset: poor; 3° subset: poor.

Techniques: Biomarker Discovery, Control

Summary Results of Base Case Analysis

Journal: ClinicoEconomics and Outcomes Research: CEOR

Article Title: Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada

doi: 10.2147/CEOR.S304395

Figure Lengend Snippet: Summary Results of Base Case Analysis

Article Snippet: The DIAMOND trial was a randomized controlled trial conducted across multiple sites in North America, in which a total of 158 adults aged ≥25 years with T1D and treated with multiple daily injections of insulin for at least 1 year previously were randomly allocated (in a 2:1 ratio) to either RT-CGM (using the Dexcom G4 platinum system) or usual care with SMBG.

Techniques:

Study characteristics and significant results, ordered by intervention and control devices.

Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: The road from intermittently scanned continuous glucose monitoring to hybrid closed-loop systems. Part B: results from randomized controlled trials

doi: 10.1177/2042018819871903

Figure Lengend Snippet: Study characteristics and significant results, ordered by intervention and control devices.

Article Snippet: Polonsky et al. Further findings from DIAMOND , 158 adults (MDI) , RT-CGM (Dexcom G4 Platinum) ( n = 105) , SMBG (Bayer Contour Next USB; n = 53) , 6 , NI , NI , NI , ↑ Hypo confidence ↓ Diabetes distress ↑ Satisfaction .

Techniques: Control